Acer Negundo Pollen Acer Saccharum Pollen Agrostis

證據等級: L5

預測適應症: 0 個

Multi-Component Allergen Extract (70-Pollen Mixture): Insufficient Data for Repurposing Analysis

One-Sentence Summary

This entry represents a complex multi-component allergen immunotherapy mixture comprising 70+ aeroallergen extracts (tree, grass, and weed pollens plus botanical roots), classically used for allergic desensitization therapy. The TxGNN pipeline returned no predicted new indications for this candidate, and the US regulatory search found no approved NDA/BLA on record. As a result, no evidence-based repurposing analysis can be performed at this time.

Quick Overview

Item	Content
Product Type	Multi-component allergen immunotherapy extract (70 components)
Original Indication	Allergen desensitization / Allergic rhinitis (inferred from product composition)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and none generated)
US Market Status	Not marketed (0 authorizations found)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This entry is not a single molecular entity but a heterogeneous mixture of 70+ allergenic source materials, including:

Tree pollens (Acer, Betula, Carya, Fagus, Fraxinus, Juglans, Juniperus, Liquidambar, Morus, Picea, Pinus, Platanus, Populus, Quercus, Salix, Ulmus, Broussonetia, Celtis, Ligustrum)
Grass pollens (Agrostis, Anthoxanthum, Avena, Bromus, Cynodon, Dactylis, Festuca, Holcus, Koeleria, Lolium, Phalaris, Phleum, Sorghum, Triticum, Zea)
Weed pollens (Ailanthus, Amaranthus spp., Ambrosia spp., Artemisia spp., Chenopodium spp., Plantago, Rumex spp., Solidago, Urtica, Xanthium)
Botanical roots/herbs (Baptisia tinctoria root, Echinacea, Fenugreek leaf, Goldenseal, Myrrh, Phytolacca americana root)

The TxGNN knowledge graph operates on single DrugBank-indexed entities. Because this mixture has no DrugBank ID and is not a defined molecular entity, the model cannot generate a drug–disease prediction score. This is a pipeline limitation, not a clinical judgment.

US Market Information

No US authorizations (NDA/BLA/ANDA) were retrieved for this product combination. Individual allergen extract components may be regulated as biological products under separate licenses; however, this specific 70-component mixture as a unit was not found in the regulatory database queried.

Safety Considerations

Please refer to the package insert for safety information. For allergen immunotherapy products generally, key considerations include risk of systemic allergic reaction (anaphylaxis), required in-office administration with post-injection observation, and contraindication in patients with severe or unstable asthma.

Conclusion and Next Steps

Decision: Hold

Rationale: This evidence pack does not represent a repurposable small-molecule drug — it is a multi-component allergen extract mixture that falls outside the TxGNN prediction framework. No predictions, regulatory data, or safety records were retrieved, making a standard repurposing evaluation impossible.

To proceed, the following is needed:

Identify the actual drug of interest: Confirm whether the intended query target is one of the botanical components (e.g., Echinacea, Goldenseal) or the mixture as a whole; individual components may have standalone DrugBank entries
Resolve the pipeline ingestion error: The candidate ID TW-UNKNOWN-multi and the concatenated multi-ingredient string suggest an upstream data parsing issue — the drug name field appears to have been populated with a full ingredient list rather than a single INN
Separate ingredients for individual analysis: If the goal is to explore any individual pollen protein or botanical compound (e.g., berberine from Goldenseal, echinacoside from Echinacea), each should be submitted as a separate query with its own DrugBank ID
Obtain MOA data (DG002): Once the correct single-entity candidate is identified, retrieve mechanism of action from DrugBank
Obtain regulatory safety data (DG001): Retrieve package insert warnings and contraindications from the relevant regulatory authority
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.